GRFS News and Press, Grifols S.A.

2026-02-26 17:27:54 ET Grifols, S.A. (GIKLY) Q4 2025 Earnings Call February 26, 2026 12:30 PM EST Company Participants Daniel Segarra - Head of Investor Relations & Sustainability and Vice President Jose Ignacio Abia Buenache - CEO & Director Roland Wandele...

HCI Group Inc. (HCI) is expected to report $4.87 for Q4 2025 XPEL Inc. (XPEL) is expected to report $0.43 for Q4 2025 Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report $0.56 for Q4 2025 UMH Properties Inc. (UMH) is expected to report $0.24 for Q4 2025 I...

Grifols S.A. (GRFS) is expected to report $0.29 for Q4 2025

2026-01-26 21:15:00 ET The following segment was excerpted from the White Falcon Capital Q4 And FY 2025 Partner Letter. ... Read the full article on Seeking Alpha For further details see: White Falcon: Q4 2025 Portfolio Positions

2025-12-28 09:10:00 ET Building on our latest Q1 update, we return to Grifols ( GRFS ) to assess recent developments. At first glance, the company reported a solid quarter; however, we remain on the sidelines. Our view has been validated so far; Grifols’ total return is down ...

2025-12-08 12:02:09 ET I've been a frequent analyst for covering Grifols, S.A. ( GRFS ) as a business here on Seeking Alpha. The world's largest blood plasma business, with other adjacent/related businesses, is going through a renaissance, rising like a phoenix from the ashes of wha...

2025-11-05 16:11:15 ET Grifols, S.A. (GIKLY) Q3 2025 Earnings Call November 4, 2025 12:30 PM EST Company Participants Daniel Segarra - Head of Investor Relations & Sustainability and Vice President Jose Ignacio Abia Buenache - CEO & Director Roland Wandeler...

2025-11-04 15:15:35 ET Biotech stocks are showing signs of recovery after years of underperformance, supported by successful drug launches, faster FDA approvals, strong trial results, and falling interest rates. M&A activity has picked up and lifted biotech stocks in general as inve...

2025-10-30 08:00:00 ET GARP Wins vs Mega-Cap Growth After years of easy money and growth-at-any-price investing, the market’s mood is bound to shift, and now is a good time to look for more reasonable valuations. With inflation still above comfortable levels, and U.S. economi...

2025-10-06 13:29:00 ET On September 17 , the Fed began cutting interest rates again, which historically preceded Big Pharma's increased activity in the M&A space.... Read the full article on Seeking Alpha For further details see: My Top 5 Biotech Stocks Big Pharm...